Effects of dasatinib on xenograft lung tumour models with YES1 overexpression

Bookmark and Share
Published: 25 Apr 2018
Views: 3653
Dr Irati Garmendia - University of Navarra, Pamplona, Spain

Dr Garmendia speaks with ecancer at AACR 2018 about patient derived xenografts (PDX) of lung tumours with high levels of YES1.

She describes how dasatinib significantly reduced tumour growth in YES1 models, and its suitability as a companion marker for treatment selection in lung cancer.